Skip to content

The Development, Implementation and Evaluation of Clinical Pathways for Chronic Obstructive Pulmonary Disease (COPD) in Saskatchewan

The Development, Implementation and Evaluation of Clinical Pathways for Chronic Obstructive Pulmonary Disease (COPD) in Saskatchewan

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03075709
Enrollment
800
Registered
2017-03-09
Start date
2017-09-30
Completion date
2021-09-30
Last updated
2018-10-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Keywords

Clinical Pathway, CPW, Chronic Obstructive Pulmonary Disease, COPD, Protocol, Adherence, Readmission, Length of Stay, Cost

Brief summary

Chronic obstructive pulmonary disease (COPD) has substantial economic and human costs. To minimize these costs high quality guidelines have been developed. However, development of guidelines alone rarely results in changes to practice. One method of integrating guidelines into professional practice is the use of clinical pathways (CPWs). The investigators are working with local stakeholders to develop CPWs for COPD with the aims of improving quality of care and guideline adherence while reducing healthcare utilization. The CPWs will utilize several steps including: standardizing diagnostic training, implementing and unifying common components of chronic disease care, coordinating the provision of education and reconditioning programs, and ensuring disease specific care utilizes and delivers evidence-informed practices. In addition, the investigators have worked to identify evidence-informed strategies for the implementation of the CPWs. Efforts are underway to tailor these implementation strategies for the local context. The investigators will conduct a three-year quantitative health services research project using an interrupted time series (ITS) design in the form of a multiple baseline approach with control groups. The CPW will be implemented in two Saskatchewan health regions (experimental groups) and two health regions will act as controls (control groups). The experimental and control groups will each contain one urban and one rural health region. This project is expected to improve quality of life and reduce healthcare utilization. The project will also provide evidence on the effects of CPWs in both urban and rural settings. If the pathways are found effective the investigators will work with all stakeholders to implement similar CPWs for the remaining health regions in the province.

Interventions

OTHERClinical Pathway (CPW)

CPWs bring the available evidence to a range of healthcare professionals by adapting guidelines to a local context and detailing the essential steps in the assessment and care of patients.

Sponsors

Lung Association of Saskatchewan
CollaboratorUNKNOWN
Novartis
CollaboratorINDUSTRY
University of Saskatchewan
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* All individuals with diagnosed chronic obstructive pulmonary disease (COPD)

Exclusion criteria

* N/A

Design outcomes

Primary

MeasureTime frameDescription
Quality of Care36 monthsOperationalized as hospital readmission rates and and emergency department (ED) presentation rates

Secondary

MeasureTime frameDescription
Healthcare Utilization36 monthsOperationalized as hospital admission rates and hospital length of stay
Guideline Adherence36 monthsOperationalized as scheduled primary care provider and specialist visits

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026